|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:age
|
6 years and older
|
|
gptkbp:alternativeTo
|
gptkb:Vi_polysaccharide_vaccine
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
J07AP01
|
|
gptkbp:boosterInterval
|
every 5 years
|
|
gptkbp:broadcastOn
|
4 doses, every other day
|
|
gptkbp:contains
|
gptkb:live_attenuated_Salmonella_Typhi
|
|
gptkbp:developedBy
|
Germanier and colleagues
|
|
gptkbp:firstLicensed
|
1989
|
|
gptkbp:form
|
enteric-coated capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ty21a vaccine
|
|
gptkbp:manufacturer
|
gptkb:Emergent_BioSolutions
|
|
gptkbp:marketedAs
|
gptkb:Vivotif
|
|
gptkbp:notRecommendedFor
|
pregnant women
immunocompromised individuals
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
mild gastrointestinal symptoms
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
typhoid fever
|
|
gptkbp:type
|
live attenuated bacterial vaccine
|
|
gptkbp:usedFor
|
prevention of typhoid fever
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Vi_polysaccharide_vaccine
|
|
gptkbp:bfsLayer
|
7
|